Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Marshall Wace LLP acquired a new position in Poseida Therapeutics, Inc. (NASDAQ:PSTXFree Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 10,538 shares of the company’s stock, valued at approximately $31,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in shares of Poseida Therapeutics in the 1st quarter worth approximately $110,000. Blair William & Co. IL increased its position in shares of Poseida Therapeutics by 41.3% in the 1st quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after buying an additional 282,310 shares in the last quarter. Vanguard Group Inc. boosted its stake in Poseida Therapeutics by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after purchasing an additional 473,746 shares during the period. Lazard Asset Management LLC boosted its stake in Poseida Therapeutics by 280.3% in the 1st quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after purchasing an additional 21,138 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its stake in Poseida Therapeutics by 177.3% in the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock worth $201,000 after purchasing an additional 40,245 shares during the period. 46.87% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Poseida Therapeutics in a research note on Tuesday, August 6th.

Get Our Latest Analysis on Poseida Therapeutics

Poseida Therapeutics Stock Down 0.4 %

Poseida Therapeutics stock opened at $2.50 on Tuesday. Poseida Therapeutics, Inc. has a twelve month low of $1.83 and a twelve month high of $4.27. The company’s 50-day moving average price is $2.89 and its two-hundred day moving average price is $2.89. The stock has a market cap of $242.40 million, a P/E ratio of -2.10 and a beta of 0.51. The company has a quick ratio of 2.48, a current ratio of 2.48 and a debt-to-equity ratio of 0.97.

Poseida Therapeutics (NASDAQ:PSTXGet Free Report) last issued its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. The firm had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. As a group, analysts expect that Poseida Therapeutics, Inc. will post -1.57 EPS for the current year.

Poseida Therapeutics Profile

(Free Report)

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.

Further Reading

Want to see what other hedge funds are holding PSTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Poseida Therapeutics, Inc. (NASDAQ:PSTXFree Report).

Institutional Ownership by Quarter for Poseida Therapeutics (NASDAQ:PSTX)

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.